Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alumis Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://www.alumis.com/
Year Founded: 2021
Status: Public
Industry Sector: HealthTechnology
CEO: Martin Babler
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -1.03
Exchange/Ticker 1: NASDAQ:ALMS
Exchange/Ticker 2: N/A
Latest Market Cap: $249,729,504
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Jan 30, 2025
Management Tracks
Wyman joins Scholar Rock
Plus: Danilkowicz to lead commercial at Alumis and an update from Precision
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Jun 29, 2024
Finance
Public Equity Report: Alumis slides after downsized IPO
Plus: Offerings by Zealand, Savara and Taysha; Savara’s PIPE; Grail reaches NASDAQ after Illumina separation
BioCentury | Jun 14, 2024
Finance
Public Equity Report: IPO action from QuantumPharm, Ascentage, Alumis, Telix
Plus: Fundraising by Avidity, Ultragenyx, ProKidney, Disc Medicine, Opthea and Replimmune
BioCentury | Jun 14, 2024
Finance
How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D
Weeks after the firm co-led Xaira’s $1B round, Michael Rome looks ahead at ‘big themes’
BioCentury | Mar 12, 2024
Data Byte
Alumis reaches new efficacy levels in oral TYK2 inhibitor field
Data from a Phase II OLE study show 90% of psoriasis patients received skin clearance of at least 75%
BioCentury | Mar 8, 2024
Finance
Trio of large, crossover-backed rounds lead week’s deals
Alumis raises $259M, Sionna $182M to pursue big opportunities in immunology, cystic fibrosis. Mammen’s FogPharma raises $145M
BioCentury | Dec 1, 2022
Management Tracks
Lee to take the helm at SK Biopharmaceuticals
Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
Items per page:
1 - 10 of 16